{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:20:07Z","timestamp":1779297607351,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist that has shown promise in the treatment of chronic kidney disease and heart failure. As its clinical use expands, understanding the adverse events associated with finerenone becomes crucial to ensuring patient safety. Prior pharmacovigilance studies have not systematically mapped finerenone-related AEs across all organ systems using global spontaneous-reporting data. We therefore aimed to identify and quantify these signals in the WHO-VigiAccess database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study employed a retrospective descriptive analysis using the reporting odds ratio (ROR), proportional reporting ratio (PRR), bayesian confidence propagation neural network (BCPNN) and empirical bayes geometric mean (EBGM) approaches to investigate reports of AEs associated with finerenone. Data were sourced from WHO\u2019s VigiAccess database, focusing on affected organ systems, symptoms, and demographic details, such as age, gender, and geographic distribution of the patients in the reports. The VigiAccess database was queried in November 2024 to collect data on AEsreported after the administration of finerenone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,482 AEs associated with finerenone were reported in VigiAccess by the end of November 2024. The analysis identified the five most frequently reported AEs, including hyperkalaemia (N = 272, ROR = 244.39), glomerular filtration rate dereased (N = 186, ROR = 684.34), blood potassium increased (N = 141, ROR = 372.63), blood creatinine increased (N = 100, ROR = 50.89), death (N = 62, ROR = 3.28), hypotension (N = 46, ROR = 5.45). The five most common categories of AEs included investigations yielding undesirable outcomes (636 cases, 26.67%), metabolism and nutrition disorders (360 cases, 15.09%), general disorders and administration site conditions (263 cases, 11.03%), gastrointestinal disorders (211 cases, 8.85%), renal and urinary disorders (159 cases, 6.67%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study highlighted the significance of monitoring AEsrelated to finerenone, with 1,482 AEs reported by November 2024. While many AEs were mild and self-limiting, some were severe, potentially leading to hospitalization or serious health implications. It is imperative for healthcare systems to engage in robust safety research and monitoring to better understand the causal relationships between finerenone and reported AEs, ensuring safer therapeutic outcomes for patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1545148","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:29:19Z","timestamp":1754544559000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongxuan","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuolin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boda","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"","journal-title":"Eur. Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"","journal-title":"J. Am. Soc. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2215\/CJN.14180920","article-title":"Management of heart failure patient with CKD","volume":"16","author":"Banerjee","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub4","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2024","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"","journal-title":"JACC Heart Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajh\/hpac124","article-title":"The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature","volume":"36","author":"Georgianos","year":"2023","journal-title":"Am. J. Hypertens."},{"key":"B17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/ehjcvp\/pvae049","article-title":"New ways of mitigating aldosterone in cardiorenal disease","volume":"10","author":"G\u00f6tzinger","year":"2024","journal-title":"Eur. Heart J. Cardiovasc Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e072686","DOI":"10.1136\/bmj-2022-072686","article-title":"Effectiveness and safety of drugs for obesity","volume":"384","author":"Henderson","year":"2024","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2412218","article-title":"Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone","author":"Huang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"105835","DOI":"10.1016\/j.phrs.2021.105835","article-title":"Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management","volume":"172","author":"Hundemer","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol. Dial. Transpl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1038\/s41598-022-13809-7","article-title":"Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety","volume":"12","author":"Luo","year":"2022","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How dangerous is hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40264-023-01281-9","article-title":"Cohort event monitoring of adverse reactions to COVID-19 vaccines in seven European countries: pooled results on first dose","volume":"46","author":"Raethke","year":"2023","journal-title":"Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ekir.2023.10.006","article-title":"Updates on new therapies for patients with CKD","volume":"9","author":"Tarun","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","article-title":"Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy","volume":"70","author":"van De Ven","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","article-title":"Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance","volume":"183","author":"Wang","year":"2023","journal-title":"JAMA Intern Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1002\/edm2.360","article-title":"Potassium management with finerenone: practical aspects","volume":"5","author":"Wanner","year":"2022","journal-title":"Endocrinol. Diabetes Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e004667","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"110592","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"819327","DOI":"10.3389\/fphar.2022.819327","article-title":"Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database","volume":"52","author":"Zhang","year":"2024","journal-title":"Infection"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1545148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:29:20Z","timestamp":1754544560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1545148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1545148"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1545148","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"article-number":"1545148"}}